INmune Bio (NASDAQ:INMB) Stock Price Down 2% – Here’s What Happened

by · The Markets Daily

INmune Bio, Inc. (NASDAQ:INMB – Get Free Report)’s stock price dropped 2% during trading on Tuesday. The stock traded as low as $1.94 and last traded at $1.96. Approximately 286,453 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 333,381 shares. The stock had previously closed at $2.00.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on INMB. Weiss Ratings upgraded shares of INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 19th. Wall Street Zen upgraded shares of INmune Bio from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, INmune Bio presently has an average rating of “Moderate Buy”.

Check Out Our Latest Analysis on INMB

INmune Bio Stock Down 2.0%

The company has a market cap of $54.39 million, a P/E ratio of -2.93 and a beta of 0.93. The stock has a 50 day moving average price of $2.12 and a two-hundred day moving average price of $1.68.

INmune Bio (NASDAQ:INMB – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.16.

Institutional Investors Weigh In On INmune Bio

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp bought a new stake in shares of INmune Bio in the second quarter valued at about $35,000. Focus Partners Advisor Solutions LLC bought a new position in INmune Bio during the second quarter worth about $71,000. GSA Capital Partners LLP bought a new position in INmune Bio during the second quarter worth about $134,000. Ieq Capital LLC acquired a new stake in INmune Bio in the 2nd quarter worth about $134,000. Finally, BlackRock Inc. bought a new stake in INmune Bio in the 2nd quarter valued at about $508,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Company Profile

(Get Free Report)

INmune Bio, Inc is a clinical-stage biotechnology company developing treatments that target the innate immune system. The company focuses on therapies designed to address chronic inflammation and immune dysfunction associated with cancer, neurodegenerative diseases and other serious medical conditions.

Its lead technology, XPro, is an engineered form of tumor necrosis factor (TNF) designed to selectively neutralize soluble TNF while preserving transmembrane TNF activity. INmune Bio is studying XPro in conditions involving neuroinflammation, including Alzheimer’s disease and treatment-resistant depression.

See Also